Advanced Cervical Cancer Pipeline Outlook Report 2025: In-Depth Insights On Clinical Development, Novel Approaches, And Market Trends

DelveInsight's, “Advanced Cervical Cancer Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the Advanced Cervical Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Cervical Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape. Click here to read more @ Advanced Liver Cancer Pipeline Outlook

Key Takeaways from the Advanced Cervical Cancer Pipeline Report

• On 17 September 2025, Ensem Therapeutics conducted a Phase 1/2, 3-part study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of ETX-636 in participants with advanced solid tumors harboring a PIK3CA mutation.
• On 11 September 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
• On 11 September 2025, Bayer organized a study treatment, BAY2927088, is expected to block the abnormal HER2 protein which may stop the spread of cancer. The trial will include about 111 participants who are at least 18 years old. All the participants will take 20 mg of BAY2927088 as tablets by mouth.
• DelveInsight's Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
• The leading Advanced Cervical Cancer Companies such as AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies , and others.
• Promising Advanced Cervical Cancer Pipeline Therapies such as Durvalumab, Cisplatin, Carboplatin, IBI310, and others.

Stay informed about the cutting-edge advancements in Advanced Cervical Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Cervical Cancer Clinical Trials Assessment

The Advanced Cervical Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Advanced Cervical Cancer Pipeline Report also highlights the unmet needs with respect to the Advanced Cervical Cancer.

Advanced Cervical Cancer Overview

Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can't usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.

Advanced Cervical Cancer Emerging Drugs Profile

• Imfinzi (durvalumab): AstraZeneca

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

• Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

• Andes 1537: Andes Biotechnologies

Andes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company's most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.

Learn more about Advanced Cervical Cancer Drugs opportunities in our groundbreaking Advanced Cervical Cancer Research and development projects @ Advanced Cervical Cancer Unmet Needs

Advanced Cervical Cancer Companies

AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.

The Advanced Cervical Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Cervical Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Cervical Cancer Treatment.
• Advanced Cervical Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Advanced Cervical Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Cervical Cancer market.

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Advanced Cervical Cancer Pipeline Products have been categorized under various Molecule types such as-

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Advanced Cervical Cancer treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Cervical Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Cervical Cancer Pipeline Report

• Coverage- Global
• Advanced Cervical Cancer Companies- AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies , and others.
• Advanced Cervical Cancer Pipeline Therapies- Durvalumab, Cisplatin, Carboplatin, IBI310 , and others.
• Advanced Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Cervical Cancer Therapeutics Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Cervical Cancer Pipeline on our website @ Advanced Cervical Cancer Emerging Drugs and Companies

Table of Content